Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 10 versus LIPOSYN III 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 10 versus LIPOSYN III 20.
LIPOSYN 10% vs LIPOSYN III 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous fat emulsion provides a source of calories and essential fatty acids as a component of parenteral nutrition. The lipid particles are metabolized similarly to endogenous chylomicrons, undergoing hydrolysis by lipoprotein lipase to release free fatty acids, which are then used for energy or stored.
Liposyn III 20% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories. It serves as a source of energy and prevents essential fatty acid deficiency by supplying triglycerides that are hydrolyzed to free fatty acids and glycerol for metabolism.
Intravenous infusion: 1-2 g/kg/day (10-20 mL/kg/day) as part of parenteral nutrition, not to exceed 2.5 g/kg/day. Infusion rate: initially 0.5-1 mL/min for 30 minutes, then increase to maximum 125 mL/hour if tolerated.
Adults: 500 mL to 2500 mL per day via continuous intravenous infusion (including peripheral or central vein); typical rate: 0.5-1 mL/kg/h initially, increasing to 1.5-2 mL/kg/h as tolerated. Maximum infusion rate: 2.5 mL/kg/h.
None Documented
None Documented
Lipid emulsion particles: elimination half-life of 10-15 minutes; triglycerides: terminal half-life of 1-3 hours, reflecting redistribution and clearance from adipose tissue; clinical context: half-life is dose-dependent and prolonged in hypertriglyceridemia, hepatic impairment, or sepsis.
The terminal elimination half-life of infused triglycerides is approximately 0.5–1 h (33–60 min). Clearance is saturable; at high infusion rates, half-life may prolong.
Renal: negligible; biliary: negligible; fecal: negligible; eliminated via peripheral lipoprotein lipase-mediated hydrolysis and subsequent metabolism of fatty acids, with CO2 production (~50-60%) and recycling into triglycerides and phospholipids; complete clearance from plasma within 24 hours of infusion cessation.
Primarily eliminated via endogenous lipid metabolic pathways (beta-oxidation in tissues). <5% excreted unchanged in urine; minimal biliary/fecal elimination.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion